These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 34439744)

  • 1. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.
    Meggyes M; Nagy DU; Balassa T; Godony K; Peterfalvi A; Szereday L; Polgar B
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
    Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
    Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3/galectin-9 interaction and its possible role during pregnancy.
    Meggyes M; Miko E; Polgar B; Bogar B; Farkas B; Illes Z; Szereday L
    PLoS One; 2014; 9(3):e92371. PubMed ID: 24651720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
    Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
    Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 6. In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15.
    Vuletić AM; Jovanić IP; Jurišić VB; Milovanović ZM; Nikolić SS; Tanić NT; Konjević GM
    Melanoma Res; 2015 Feb; 25(1):22-34. PubMed ID: 25380182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tim-3 Is Upregulated in NK Cells during Early Pregnancy and Inhibits NK Cytotoxicity toward Trophoblast in Galectin-9 Dependent Pathway.
    Sun J; Yang M; Ban Y; Gao W; Song B; Wang Y; Zhang Y; Shao Q; Kong B; Qu X
    PLoS One; 2016; 11(1):e0147186. PubMed ID: 26789128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research progress on T-cell immunoglobulin mucin 3/galectin 9 (TIM-3/galectin-9) in tumour immunity].
    Ma L; Bai L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Aug; 40(8):754-760. PubMed ID: 39215674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
    Smyth MJ; Swann J; Kelly JM; Cretney E; Yokoyama WM; Diefenbach A; Sayers TJ; Hayakawa Y
    J Exp Med; 2004 Nov; 200(10):1325-35. PubMed ID: 15545356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.
    Moseman JE; Foltz JA; Sorathia K; Heipertz EL; Lee DA
    Cytotherapy; 2020 Jun; 22(6):322-328. PubMed ID: 32278551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Galectin-9/TIM-3 pathway in the systemic inflammatory response in early-onset preeclampsia.
    Miko E; Meggyes M; Bogar B; Schmitz N; Barakonyi A; Varnagy A; Farkas B; Tamas P; Bodis J; Szekeres-Bartho J; Illes Z; Szereday L
    PLoS One; 2013; 8(8):e71811. PubMed ID: 23936526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.
    Wang W; Guo H; Geng J; Zheng X; Wei H; Sun R; Tian Z
    J Biol Chem; 2014 Nov; 289(48):33311-9. PubMed ID: 25315772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells.
    Bergmann C; Wild CA; Narwan M; Lotfi R; Lang S; Brandau S
    Eur J Immunol; 2011 Dec; 41(12):3564-73. PubMed ID: 21905023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.
    Szereday L; Meggyes M; Berki T; Miseta A; Farkas N; Gervain J; Par A; Par G
    Clin Exp Med; 2020 May; 20(2):219-230. PubMed ID: 32108916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model.
    Kim JE; Cho HS; Yang HS; Jung DJ; Hong SW; Hung CF; Lee WJ; Kim D
    Immunobiology; 2012 Sep; 217(9):873-81. PubMed ID: 22306178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy.
    Yang R; Hung MC
    Sci China Life Sci; 2017 Oct; 60(10):1058-1064. PubMed ID: 29027155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The breast tumor microenvironment alters the phenotype and function of natural killer cells.
    Krneta T; Gillgrass A; Chew M; Ashkar AA
    Cell Mol Immunol; 2016 Sep; 13(5):628-39. PubMed ID: 26277898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Killer Cells Induce CD8
    Liu S; Xu C; Yang F; Zong L; Qin Y; Gao Y; Su Q; Li T; Li Y; Xu Y; Zheng M
    Front Immunol; 2022; 13():884290. PubMed ID: 35874664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.